DXD

DXD Liste de produits

Attribut
Antibody (3)
Bibliothèque de produits
En ligne (3)
Espèces
Mouse (3)
Étiquette
- (2)Mouse IgG1 (1)
Marqueur
Unconjugated (1)HRP Labeled (1)Biotin-labeled (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
HOT DXD-M684	Mouse	HEK293	Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1	Ajouter au panier
DXD-BVM807	Mouse	HEK293	Biotinylated Anti-DXD&Exatecan Antibody, Mouse IgG1, Avitag™	Ajouter au panier
DXD-PLM684	Mouse	HEK293	HRP conjugated Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1	Ajouter au panier

Quantité totale3

DXDContexte de la molécule

Dxd (Exatecan ADC derivative) is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 uM for targeting ADCs (DS-8201A). Dxd was cytotoxic to human tumor cell lines KPL-4, NCI-N87 and SK-BR, 3 and the IC50s of MDA-MB-468 was 1.43 NM-4.07 nM, while lgGADC (Dxd as payload) had no inhibitory effect on HER2 expression in the 4 cell lines. DS8201a (Dxd as payload) had a significant inhibitory effect on HER2-positive KPL-4 and NCI cell lines N87 and SK-BRwith IC50 values of 26.8, 25.4 and 6.7 ng/mL, respectively, but had no inhibitory effect on MDA MB-468 (IC50, > 10000 - mL). HRP-anti-DXD-antibody is a conjugation product of HRP and anti-DXD-antibody. It can be used in PK, PD analysis and ELISA.

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Tifcemalimab	TAB-004; JS-004	Phase 3 Clinical	Shanghai Junshi Biosciences Co Ltd	Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hodgkin Disease; Nasopharyngeal Carcinoma; Lymphoma; Lung Neoplasms; Melanoma; Neoplasm Metastasis	Details
ANB-032	ANB-032	Phase 2 Clinical	Anaptysbio Inc	Inflammation; Dermatitis, Atopic; Eczema	Details
Venanprubart	LY-3361237	Phase 2 Clinical	Sanford-Burnham Medical Research Institute, Eli Lilly And Company	Sjogren's Syndrome; Lupus Erythematosus, Systemic; Psoriasis	Details
MB-272	MB272; GS-0272	Phase 1 Clinical	University Of Oxford	Arthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic	Details
HFB-200603	HFB-200603	Phase 1 Clinical	HiFiBiO Therapeutics	Carcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung	Details